Article: Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

Article - Media, Publications

Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

Yahoo Finance, 06 January 2021

Daix (France), January 5, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the details of the Phase III clinical trial with its lead drug candidate lanifibranor in NASH following the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA) and the receipt of the Scientific Advice letter from the European Medicines Agency (EMA). The Phase III trial design and clinical strategy have been discussed with both regulatory authorities and the following key points can be confirmed:

Seeking of U.S. accelerated approval and EU conditional approval for lanifibranor to be based on a 72-week histology analysis – Inventiva will seek to obtain accelerated approval in the U.S. and conditional approval in the EU for lanifibranor based on a pre-specified histology analysis in approximately 900 patients after 72 weeks establishing a positive benefit-risk ratio.

Read Full Article

Article: INVENTIVA to Participate in the “ROTH Battle of the NASH Thrones Investor Conference”

Article - Media, Publications

INVENTIVA to Participate in the “ROTH Battle of the NASH Thrones Investor Conference”

Yahoo Finance, 12 October 2018

Daix (France), October 12, 2018 – Inventiva S.A. (“Inventiva” or the “Company”), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS), today announced that Pierre Broqua, Chief Scientific Officer and co-founder of Inventiva, will participate in the upcoming “ROTH Battle of the NASH Thrones Investor Conference” being held on October 17, 2018 at the Park Hyatt New York hotel, New York, USA.

Pierre Broqua will be speaking in the panel entitled “House of PPARs vs. House of THR-beta”, one of the conference`s four panel discussions covering topics currently at the forefront of drug development in NASH.

Read Full Article

Article: Six former UBS forex staff banned by Swiss watchdog

Article - Media, Publications

Six former UBS forex staff banned by Swiss watchdog

Silke Koltrowitz, Steve Slater, Kirstin Ridley, 17 December 2015

Six former UBS managers and traders have been banned for up to five years for alleged manipulation of foreign exchange and precious metals markets in the first sanctions handed out by authorities in a global investigation. Continue reading “Article: Six former UBS forex staff banned by Swiss watchdog”

Article: Arrested RBS forex trader named as Paul Nash: sources

Article - Media, Publications

Arrested RBS forex trader named as Paul Nash: sources

Jamie McGeever, Kirstin Ridley, 08 January 2015

LONDON (Reuters) – Royal Bank of Scotland currency trader Paul Nash has become the first individual arrested in connection with a global inquiry into alleged manipulation in the foreign exchange market, sources familiar with the matter said on Thursday.

Nash, who was suspended by RBS in 2013, was named by the sources as the man arrested in Billericay, southeast England, on Dec. 19. One of the sources said his arrest came only days before he emigrated to Canada.

Nash emigrated to Canada on Christmas Day and has rented out his family home, the source said. His arrest was not by appointment, as is typical in such cases, but was an “arrest and raid”, the source added.

Nash, who has not been charged with any offense, appeared at Westminster Magistrates’ Court on Dec. 23 over variations to his bail conditions, a court official confirmed. These included that he would reside at a specified address in British Columbia.

Britain’s Serious Fraud Office (SFO) said only that a 48-year-old man had appeared at the London court on Dec. 23 in connection with a global investigation into allegations of manipulation in the $5.3 trillion-a-day forex market.

The increasingly aggressive agency, which is preparing for the trials this year of individuals alleged to have manipulated global benchmark interest rates, said last July that it might file the first charges in the high-profile inquiry this year.

About 30 forex traders have been put on leave, suspended or fired as prosecutors and regulators continue to examine allegations of wrongdoing in the world’s largest market.

Read Full Article